의약품 관련 법령
Assessing User Fees Under the Biosimilar User Fee Amendments of 2017 Guidance for Industry
| 작성자 | 관리자 | ||
|---|---|---|---|
| 작성일 | 2018-07-31 | 조회수 | 704 |
| 국가정보 | 북 아메리카>미국 | ||
| 출처 | FDA | ||
| 원문 | https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM584984.pdf | ||
| 첨부파일 | |||
Assessing User Fees Under the Biosimilar User Fee Amendments of 2017 Guidance for Industry.pdf(447.28KB)Assessing User Fees Under the Biosimilar User Fee Amendments of 2017 Guidance for Industry
- 이전글 Major Depressive Disorder: Developing Drugs for Treatment
- 다음글 Oncology Therapeutic Radiopharmaceuticals: Nonclinical Studies and Labeling Recommendations Guidance for Industry
